HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Souder Bill Follows White House Meth Strategy; Highlights Import, Super Labs

This article was originally published in The Tan Sheet

Executive Summary

Pseudoephedrine importers and exporters would be required to file with the Department of Justice before transferring sale of the meth precursor to a new buyer as part of a bill introduced by Rep. Mark Souder (R-Ind.) Sept. 22

You may also be interested in...



Pseudoephedrine Sales Limit Provisions Attached To Patriot Act

The Talent/Feinstein Combat Meth Act (S 103) that would place behind-the-counter restrictions on pseudoephedrine was added to the Patriot Act reauthorization package in conference discussions Nov. 17

Meth bill clears Senate

The Senate passes the Commerce, Justice & Science Appropriations bill containing the Combat Meth Act Sept. 15. The anti-meth legislation was added to the CJS appropriations bill Sept. 9 (1"The Tan Sheet" Sept. 12, 2005, p. 5). The bill, which would put pseudoephedrine-containing products behind the counter, now heads to conference committee. The House previously approved the CJS appropriations bill without the anti-meth legislation...

White House Meth Bill Plan Would Not Put Pseudoephedrine Behind Counters

The Bush Administration supports federal meth legislation that would apply significantly fewer restrictions on pseudoephedrine than the pending Talent/Feinstein senate bill

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS127377

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel